

To,

The Manager-Listing

02.04.2024

National Stock Exchange of India Ltd

Mumbai.

BSE Limited

Mumbai.

Dear Sir,

Sub: Reporting of Initial Disclosure to be made by entity as Large Corporate.

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, read with SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/049 dated March 31, 2023, we confirm that Bal Pharma Limited is not a Large Corporate as per the applicability criteria mentioned in Chapter XII - Clause 1.2 of the said Operational Circular for the financial year 2023-24. The details required as per Annexure A of the said circular are enclosed.

Please take this intimation on record.

For Bal Pharma Limited

SHAILES

Digitally signed by SHAILESH SIROYA
Dix c-IN, or-Peronal.

Authorized Signatory



Annexure A

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate.

SI No	Particulars	Details
01	Name of the Company	Bal Pharma Limited
02	CIN Number	L85110KA1987PLC008368
03	Outstanding borrowing of company as on 31st March 2024, as applicable (in Rs cr)	Rs. 44.81Crores.
04	Highest Credit Rating During the previous FY along with name of the Credit Rating Agency	BBB - ACUITE Rating & Research.
05	Name of Stock Exchange in which the fine shall be paid, in case of shortfall in the required borrowing under the framework.	Not applicable

We confirm that <u>we are not a Large Corporate</u> as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

For Bal Pharma Limited

Authorized Signatory